Halftime Portfolio: Accuray takeout?
CNBC Videos by CNBC Videos 3:23 mins
In the battle for the top trader of the year, Jon Najarian discusses his play on Accuray after a weak month.
Pauv I really enjoyed reading your response. No matter what Varian could be exposed of, bottom line Accuray has to turn a profit or the big guys will be selling off or Aray will be offering more shares diluting the company s/p.
They must feel Accuray is worth something or waiting for an announcement that someone is buying them out...I am leaning towards a buyout.
ViewRay no longer focused on IPO: MRI maker withdraws plans to go public
ViewRay, which markets the first and only FDA-approved MRI-guided radiation therapy system, withdrew its plans for an initial public offering on Thursday.
The company had planned to raise $52 million at a fully diluted market cap of $204 million by listing on the NASDAQ under the symbol VRAY but postponed the offering in early April.
Close peer Accuray (NASDAQ: ARAY) is up over 20% year-to-date after a disappointing performance in 2014.
The Oakwood Village, OH-based company was founded in 2004 and booked $6 million in sales for the fiscal year ended December 31, 2014. Cowen & Company and Stifel were set to be the joint book runners on the deal.
Neither was MAKO MAKO Surgical Corp did make a dime and was bought out for $30.00 ashare go figured
Bemoore it was a news letter called Up stocks. News letter
It's a news letter which one not sure. I will ask my fellow trader. The volume is attracting a lot of attention
the perfect storm but then there is earnings announcement April 29th...hummmmm
See cancer, treat cancer: ViewRay sets terms for $52 million IPO
ViewRay, which markets the only MRI radiation therapy system that images and treats patients simultaneously, announced terms for its IPO on Friday. The Oakwood Village, OH-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, ViewRay would command a fully diluted market value of $204 million.
ViewRay, which was founded in 2004 and booked $6 million in sales for the 12 months ended December 31, 2014, plans to list on the NASDAQ under the symbol VRAY. Cowen & Company and Stifel are the joint bookrunners on the deal. It is expected to price during the week of March 23, 2015.
See headlines under summary